| Selected Balance Sheet Data |
Note 3. Selected Balance Sheet Data:
Inventories:
Inventories consist of (in thousands):
|
|
|
|
|
|
|
|
|
|
September 30, |
|
June 30, |
|
|
|
2025 |
|
2025 |
|
Raw materials |
|
$ |
93,993 |
|
$ |
89,080 |
|
Finished goods(1) |
|
|
114,878 |
|
|
106,188 |
|
Inventories |
|
$ |
208,871 |
|
$ |
195,268 |
|
| (1) |
Finished goods inventory of $5,683 and $5,822 is included within Other Assets in the September 30, 2025 and June 30, 2025, Condensed Consolidated Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the Condensed Consolidated Balance Sheets dates.
|
Property and Equipment:
Property and equipment consist of (in thousands):
|
|
|
|
|
|
|
|
|
|
September 30, |
|
June 30, |
|
|
|
2025 |
|
2025 |
|
Land |
|
$ |
8,133 |
|
$ |
8,151 |
|
Buildings and improvements |
|
|
256,737 |
|
|
254,355 |
|
Machinery and equipment |
|
|
244,188 |
|
|
245,924 |
|
Construction in progress |
|
|
20,257 |
|
|
23,420 |
|
Property and equipment, cost |
|
|
529,315 |
|
|
531,850 |
|
Accumulated depreciation and amortization |
|
|
(288,981) |
|
|
(286,131) |
|
Property and equipment, net |
|
$ |
240,334 |
|
$ |
245,719 |
|
Intangible Assets:
Intangible assets consist of (in thousands):
|
|
|
|
|
|
|
|
September 30, |
|
June 30, |
|
|
2025 |
|
2025 |
|
Developed technology |
$ |
579,531 |
|
$ |
620,062 |
|
Tradenames |
|
94,393 |
|
|
152,648 |
|
Customer relationships |
|
210,431 |
|
|
212,800 |
|
Patents |
|
5,062 |
|
|
4,967 |
|
Other intangibles |
|
7,145 |
|
|
7,174 |
|
Definite-lived intangible assets |
|
896,562 |
|
|
997,651 |
|
Accumulated amortization |
|
(546,455) |
|
|
(632,052) |
|
Total intangible assets, net |
$ |
350,107 |
|
$ |
365,599 |
|
Changes to the carrying amount of net intangible assets for the period ended September 30, 2025 consist of (in thousands):
|
|
|
|
|
|
September 30, |
|
|
2025 |
Beginning balance |
|
$ |
365,599 |
Other additions |
|
|
95 |
Amortization expense |
|
|
(15,498) |
Currency translation |
|
|
(89) |
Ending balance |
|
$ |
350,107 |
The estimated future amortization expense for intangible assets as of September 30, 2025 is as follows (in thousands):
|
|
|
|
Remainder 2026 |
|
$ |
46,256 |
2027 |
|
|
58,682 |
2028 |
|
|
54,951 |
2029 |
|
|
40,870 |
2030 |
|
|
26,911 |
Thereafter |
|
|
122,437 |
Total |
|
$ |
350,107 |
Goodwill:
Changes to the carrying amount of goodwill for the period ended September 30, 2025 consist of (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics and |
|
|
|
|
Protein Sciences |
|
Spatial Biology |
|
Total |
June 30, 2025 |
|
$ |
426,776 |
|
$ |
554,159 |
|
$ |
980,935 |
Currency translation |
|
|
(1,975) |
|
|
(48) |
|
|
(2,023) |
September 30, 2025 |
|
$ |
424,801 |
|
$ |
554,111 |
|
$ |
978,912 |
We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2025. No indicators of impairment were identified as part of our assessment.
Other assets:
Other assets consist of (in thousands):
|
|
|
|
|
|
|
|
|
September 30, |
|
June 30, |
|
|
2025 |
|
2025 |
Equity method investment in Wilson Wolf |
|
$ |
234,925 |
|
$ |
235,983 |
Long-term inventory |
|
|
5,683 |
|
|
5,822 |
Investment in Spear Bio |
|
|
15,000 |
|
|
15,000 |
Investment in MDxHealth(1) |
|
|
8,682 |
|
|
— |
Notes receivable(1) |
|
|
7,744 |
|
|
2,184 |
Other |
|
|
4,529 |
|
|
24,927 |
Other assets |
|
$ |
276,563 |
|
$ |
283,916 |
|
(1) |
Amounts relate to the completed divestitures of the Company’s held-for-sale assets. |
|